1401O - Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG...
多中心的Ⅲ期临床试验,主要研究终点为研究者(investigator,INV)评估的无进展生存期(progression-free survival,PFS),次要研究终点包括独立评审委员会(Independent Review Committee,IRC)评估的PFS、总生存期(overall survival,OS)、客观缓解率(objective response rate...
1. Leon-Ferre RA, et al. The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negativeand HER2-Positive Breast Cancer Ann Surg Oncol, 2021.28(4): p.2111-2119. 2. de Nonneville A,et al. Pathological complete response rate and disease-free survival afterneoadjuvant chemotherapy in patients ...
Georgia on March 29 to April 3, 2019 by medical student Ross Mudgway and Sharon Lum, medical director of the Breast Health Center at Loma Linda University, on the survival rate of patients with human epidermal growth factor receptor two (HER2)-positive, stage IV breast cancer who underwent ...
[6] Guarneri V, Griguolo G, Miglietta F, Conte PF, Dieci MV, Girardi F. Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomised trials. Ann Oncol. 2021;32:S407. ...
months with a hazard ratio of 0.76. This statistical significance prompted the first of two interim overall survival analyses. At this time, the survival analysis was immature with only 53% of events, but it was not positive. It did not demonstrate a difference between the two treatment arms....
It randomly allocated patients in a 1:4 ratio with centrally confirmed, HER2-positive, stage I-IIIA invasive, operable breast cancer with at least one PET-evaluable lesion to either group A, where patients received docetaxel (75 mg/m2, intravenous), carboplatin (area under the curve 6 mg/mL...
Data from a basket study, looking at T-DXd in these HER2-low-positive breast cancer patients found a response rate that was about 40% and a progression-free survival of around 11 months. Given this very promising early data, there is a randomized registration study, DESTINY-Breast04. We’...
中文摘要: 目的:探讨曲妥珠单抗联合化疗对人表皮生长因子受体2(HER2)阳性晚期胃癌患者疗效及血清肿瘤标志物的影响。方法:将74例确诊为晚期胃癌且HER2呈阳性表达的患者根据入院先后顺序分为观察组和对照组,各37例。对照组患者接受顺铂+卡培他滨化疗;观察组患者在对照组治疗基础上,于化疗第1天加用曲妥珠单抗静脉滴注,...
The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 6, 116–124 (2020). PubMed Google Scholar Turner, N. C. et al. Overall survival ...